180 related articles for article (PubMed ID: 29989453)
1. Emerging targets in advanced non-small-cell lung cancer.
Valentino F; Borra G; Allione P; Rossi L
Future Oncol; 2018 Jun; 14(13s):61-72. PubMed ID: 29989453
[TBL] [Abstract][Full Text] [Related]
2. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
3. New options on the horizon for nononcogene addicted non-small-cell lung cancer.
Paglialunga L; Ricciardi S; D'Arcangelo M
Future Oncol; 2018 Jun; 14(13s):19-28. PubMed ID: 29989449
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K; Funaguchi N; Nakano T
J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
6. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.
Favoni RE; Alama A
Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
8. [THE CURRENT APPROACH TO ADVANCED LUNG CANCER].
Gottfried M; Keizman D; Mishaeli M; Maimon Rabinovich N
Harefuah; 2015 Aug; 154(8):521-4, 539-40. PubMed ID: 26480619
[TBL] [Abstract][Full Text] [Related]
9. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Langhammer S; Scheerer J
Oncotarget; 2017 Jun; 8(26):43555-43570. PubMed ID: 28402937
[TBL] [Abstract][Full Text] [Related]
10. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
11. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
Capelletto E; Novello S; Scagliotti GV
Future Oncol; 2014 May; 10(6):1081-93. PubMed ID: 24941991
[TBL] [Abstract][Full Text] [Related]
12. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of targeted agents monotherapy in advanced NSCLC.
Zhang Q; Wu YL
Expert Rev Clin Pharmacol; 2016; 9(1):143-55. PubMed ID: 26558941
[TBL] [Abstract][Full Text] [Related]
14. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
16. ["Targeted Therapies" in NSCLC - present and future].
Pall G; Hilbe W
Wien Med Wochenschr; 2007; 157(21-22):545-53. PubMed ID: 18157592
[TBL] [Abstract][Full Text] [Related]
17. Future options for ALK-positive non-small cell lung cancer.
Iacono D; Chiari R; Metro G; Bennati C; Bellezza G; Cenci M; Ricciuti B; Sidoni A; Baglivo S; Minotti V; Crinò L
Lung Cancer; 2015 Mar; 87(3):211-9. PubMed ID: 25601484
[TBL] [Abstract][Full Text] [Related]
18. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
19. New and emerging targeted treatments in advanced non-small-cell lung cancer.
Hirsch FR; Suda K; Wiens J; Bunn PA
Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
[TBL] [Abstract][Full Text] [Related]
20. Onartuzumab in lung cancer: the fall of Icarus?
Rolfo C; Van Der Steen N; Pauwels P; Cappuzzo F
Expert Rev Anticancer Ther; 2015 May; 15(5):487-9. PubMed ID: 25818471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
